Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

29 juin 2026 05h00 HE | Source: Resalis Therapeutics SRL

Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity

Torino, Italy, June 29, 2026 – Resalis Therapeutics today announced the dosing of the first participant in a Phase 1b clinical study of its lead candidate, RES-010, a novel antisense oligonucleotide...
22 janv. 2026 05h00 HE | Source: Resalis Therapeutics SRL

Resalis Therapeutics Appoints Sandor Batkai as Medical Director

Torino, Italy, January 22 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, today announced the appointment of Sandor Batkai, MD, PhD, as Medical Director. Dr....
07 oct. 2025 05h00 HE | Source: Resalis Therapeutics SRL

Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class...